Peptides DB
Research-centric peptide and protocol reference hub
Study 3 of 9Hexarelin literaturePubMed2023

Revealing the interaction between peptide drugs and permeation enhancers in the presence of intestinal bile salts.

The study highlights how permeability enhancers can alter peptide interactions at a molecular level, which may influence drug release profiles, but these findings are based on simulations and not direct human evidence.

Read at PubMedAdd to compare

Where it sits

this study against the rest of the hexarelin corpus
4
Preclinical · this one
5
Observational
0
Open-label
0
Randomised
0
Reviews

Summary and findings

This study investigated the interactions between permeability enhancers (sodium caprate and SNAC) and four peptides (including hexarelin) in the presence of taurocholate. The research utilized all-atom molecular dynamics simulations to assess how these interactions affect peptide release profiles. No therapeutic claims are made.

How much of this paper we could read: partial text (0.60). We had some abstract detail. Check the source for anything decisive. What this means →
Not reported in abstract.2023

Abstract

The authors’ words, as PubMed supplied them

Permeability enhancer-based formulations offer a promising approach to enhance the oral bioavailability of peptides. We used all-atom molecular dynamics simulations to investigate the interaction between two permeability enhancers (sodium caprate, and SNAC), and four different peptides (octreotide, hexarelin, degarelix, and insulin), in the presence of taurocholate, an intestinal bile salt. The permeability enhancers exhibited distinct effects on peptide release based on their properties, promoting hydrophobic peptide release while inhibiting water-soluble peptide release. Lowering peptide concentrations in the simulations reduced peptide-peptide interactions but increased their interactions with the enhancers and taurocholates. Introducing peptides randomly with enhancer and taurocholate molecules yielded dynamic molecular aggregation, and reduced peptide-peptide interactions and hydrogen bond formation compared to peptide-only systems. The simulations provided insights into molecular-level interactions, highlighting the specific contacts between peptide residues responsible for aggregation, and the interactions between peptide residues and permeability enhancers/taurocholates that are crucial within the mixed colloids. Therefore, our results can provide insights into how modifications of these critical contacts can be made to alter drug release profiles from peptide-only or mixed peptide-PE-taurocholate aggregates. To further probe the molecular nature of permeability enhancers and peptide interactions, we also analyzed insulin secondary structures using Fourier transform infrared spectroscopy. The presence of SNAC led to an increase in β-sheet formation in insulin. In contrast, both in the absence and presence of caprate, α-helices, and random structures dominated. These molecular-level insights can guide the design of improved permeability enhancer-based dosage forms, allowing for precise control of peptide release profiles near the intended absorption site.

Background

The paper addresses the challenge of peptide drug absorption in the gastrointestinal tract, which is often limited by the presence of bile salts. Previous studies have indicated that permeation enhancers may improve the bioavailability of peptides. This study is significant as it explores the specific interactions between Hexarelin and these enhancers in a bile salt environment.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.

Elsewhere in the Hexarelin corpus

CGHSR agonism increases blood glucose but delays food intake in GHSR hyperresponsive rats.europepmc · 2026 · n=30 · Not reported in abstract.AnimalCHexarelin promotes the survival of retinal ganglion cells after optic nerve transection.europepmc · 2026 · Survival rates of RGC in saline, 25 μg/kg, 50 μg/kg, and 100 μg/kg hexarelin-treated hamsters were 51.2%, 62.4%, 68.5%, and 74.6%, respectively, in 7 days ONT.AnimalCGrowth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.europepmc · 2026 · Not reported in abstract.AnimalBInvestigating the impact of COVID-19 on performance and image enhancing drug usebiorxiv-preprint · 2021 · 45% reported a change in PIED use during lockdown, n=27.HumanCHexarelin promotes the survival of retinal ganglion cells after optic nerve transection.PubMed · 2026 · Survival rates of RGCs were 74.6% at 100 μg/kg hexarelin after 7 days ONT.AnimalDSemantic Scholar search for HexarelinSemanticScholar · 2010